Osimertinib: Anticancer drug, protein kinase inhibitor
Adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations. Treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations. Treatment